Patents Assigned to Vycellix, Inc.
  • Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages
    Patent number: 12533338
    Abstract: The present invention comprises a method of downregulating intracellular defenses by administering (5Z)-7-Oxozeaenol. This allows for improved delivery of RNA based gene vectors to natural killer, stem and macrophage cells. The resulting cells can be used in adoptive cell transfer therapies. Also provided are methods of treating virally induced inflammation via administration of (5Z)-7-Oxozeaenol together with an anti viral therapeutic.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: January 27, 2026
    Assignee: VYCELLIX, INC.
    Inventors: Evren Alici, Adil Duru, Tolga Sutlu
  • NOVEL RNA CONSTRUCT AND METHODS OF USE THEREOF FOR ENHANCING THE THERAPEUTIC EFFECTS OF CYTOTOXIC CELLS AND STEM CELLS
    Publication number: 20250332187
    Abstract: The present invention comprises Rig I agonists for enhancing the effects of cytotoxic cells and stem Cells. The Rig I agonists can be used in vivo as small molecule therapeutics or in vitro to enhance cells for adoptive cell transfer. Applications include cancer therapy, immune system enhancement, chronic viral infection and treatment of viral induced inflammation and enhancement of virus based therapies.
    Type: Application
    Filed: October 24, 2024
    Publication date: October 30, 2025
    Applicant: VYCELLIX, INC.
    Inventor: Evren ALICI
  • RNA construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
    Patent number: 12128061
    Abstract: The present invention comprises Rig I agonists for enhancing the effects of cytotoxic cells and stem Cells. The Rig I agonists can be used in vivo as small molecule therapeutics or in vitro to enhance cells for adoptive cell transfer. Applications include cancer therapy, immune system enhancement, chronic viral infection and treatment of viral induced inflammation and enhancement of virus based therapies.
    Type: Grant
    Filed: September 30, 2018
    Date of Patent: October 29, 2024
    Assignee: VYCELLIX, INC.
    Inventor: Evren Alici
  • MODULATORS OF THE IMMUNE ESCAPE MECHANISM FOR UNIVERSAL CELL THERAPY
    Publication number: 20230272035
    Abstract: Therapeutic agents capable of detaining bulky proteins such as CD45, CD148, and CD43 in the middle of the cellular interface between a graft cell and CD45 positive host effector cell (such as a T cell, NK cell, B cell, or dendritic cell) are disclosed, as are methods for their use and products made with such therapeutic agents. The therapeutic agents prevent or inhibit the formation of functional immunologic synapses (including physiological SMAC). They also result in continuous dephosphorylation of signal transduction pathways.
    Type: Application
    Filed: December 7, 2020
    Publication date: August 31, 2023
    Applicant: VYCELLIX, INC.
    Inventors: Evren ALICI, Alamdar HUSSAIN
  • NOVEL RNA CONSTRUCT AND METHODS OF USE THEREOF FOR ENHANCING THE THERAPEUTIC EFFECTS OF CYTOTOXIC CELLS AND STEM CELLS
    Publication number: 20190076463
    Abstract: The present invention comprises Rig I agonists for enhancing the effects of cytotoxic cells and stem Cells. The Rig I agonists can be used in vivo as small molecule therapeutics or in vitro to enhance cells for adoptive cell transfer. Applications include cancer therapy, immune system enhancement, chronic viral infection and treatment of viral induced inflammation and enhancement of virus based therapies.
    Type: Application
    Filed: September 30, 2018
    Publication date: March 14, 2019
    Applicant: Vycellix, Inc.
    Inventor: Evren Alici